Bioasis Technologies is now ranked among the top 25 undervalued dividend-paying stocks on the TSX Venture Exchange (TSXV). A stock is considered undervalued if it trades at a discount to its valuation – a calculation used to determine the intrinsic (true) worth of a company. Valuation methodology provided by Stockcalc (see below).
All data provided as-at market close February 21, 2023. The list is sorted by stocks with the greatest percentage difference between valuation and price. Companies included above paid a dividend in the last 12-months. Bioasis Technologies Bioasis Technologies Inc is a biopharmaceutical company developing xB3, a proprietary technology for the delivery of therapeutics across the blood-brain barrier and the treatment of CNS disorders, including brain cancers and neurodegenerative diseases. Bioasis Technologies is listed under BTI on the TSX Venture Exchange.
More about Bioasis Technologies
Stocks in this category are held primarily for potential income and capital appreciation. Dividend stocks showing a higher valuation than their current price have both potential upside and ability to sustain or grow their dividend.
Artificial intelligence at Report on Business
Artificial Intelligence at Report on Business Report on Business scans market data using algorithms to process large quantities of information. The results are specialized reports produced through automation. Ongoing ROB project experiments that leverage artificial intelligence include valuation screens across 14 categories and end-of-day Closing Summary reports for all North American securities.